Fingolimod treatment for multiple sclerosis patients what do we do with varicella?

Annals of Neurology

Volumn 70, Issue 4, 2011, Pages 673-674

  Winkelmann, Alexander ^a   Loebermann, Micha ^a   Reisinger, Emil C ^a   Hartung, Hans Peter ^b   Zettl, Uwe K ^a  

^a UNIVERSITY OF ROSTOCK   (Germany)

^b HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CHICKENPOX VACCINE; FINGOLIMOD; IMMUNOGLOBULIN G ANTIBODY; DRUG DERIVATIVE; IMMUNOSUPPRESSIVE AGENT; PROPANEDIOL DERIVATIVE; SPHINGOSINE;

ANTIBODY SPECIFICITY; ANTIBODY TITER; CHICKENPOX; DISEASE COURSE; DRUG EFFICACY; FOOD AND DRUG ADMINISTRATION; HUMAN; IMMUNIZATION; LETTER; MULTIPLE SCLEROSIS; NONHUMAN; PRIORITY JOURNAL; TREATMENT CONTRAINDICATION; TREATMENT RESPONSE; VARICELLA ZOSTER VIRUS; ANIMAL; NOTE;

ANIMALS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MULTIPLE SCLEROSIS; PROPYLENE GLYCOLS; SPHINGOSINE;

EID: 84855410645     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.22605     Document Type: Letter

References (7)

1. Cohen JA, Chun J. Mechanisms of fingolimod's efficacy and adverse effects in multiple sclerosis. Ann Neurol 2011;69:759-777.
2. Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010;362:402-415.
3. Gilenya: EPAR-product information. March 30, 2011 ed. London, UK: European Medicines Agency, 2011.
4. Gilenya-approved labeling text. September 21, 2010 ed. Silver Spring, MD: US Food and Drug Administration, 2010.
5. Perella D, Fiks AG, Jumaan A, et al. Validity of reported varicella history as a marker for varicella zoster virus immunity among unvaccinated children, adolescents, and young adults in the postvaccine licensure era. Pediatrics 2009;123:e820-e828.
6. Loebermann M, Borso D, Hilgendorf I, et al. Immunization in the adult immunocompromised host. Autoimmun Rev 2011 May 18 (Epub ahead of print). DOI: 10.1016/j.autrev.2011.05.015.
7. Ross RT, Nicolle LE, Cheang M. The varicella zoster virus: A pilot trial of a potential therapeutic agent in multiple sclerosis. J Clin Epidemiol 1997;50:63-68. (Pubitemid 27089208)